Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | Zendy

Aaron Galaznik | Zendy; Rachel Huelin | Zendy; M. Stokes | Zendy; Yelan Guo | Zendy; Meredith Hoog | Zendy; Tarun Bhagnani | Zendy; Jill A. Bell | Zendy; Yaping Shou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma

Author(s) -

Aaron Galaznik,

Rachel Huelin,

M. Stokes,

Yelan Guo,

Meredith Hoog,

Tarun Bhagnani,

Jill A. Bell,

Yaping Shou

Publication year - 2018

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.4155/fsoa-2018-0049

Subject(s) - follicular lymphoma , lymphoma , diffuse large b cell lymphoma , medicine , refractory (planetary science) , oncology , cancer research , biology , astrobiology

To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012–May 2016. Among 33 included articles, therapies included stem cell transplant (SCT) and chemotherapy, including experimental regimens. The highest overall survival rates were observed for SCT, long considered an optimal strategy following initial relapse. Prognoses were inferior among DLBCL patients receiving rituximab-based regimens rather than SCT, particularly among studies that exclusively focused on those ineligible for SCT due to age or co-morbidity. A lack of viable treatment options for DLBCL/FL patients ineligible for SCT after relapse remains a significant gap in care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research